Fortive reported Q2 2025 adjusted diluted earnings per share of $0.58, narrowly missing consensus estimates of $0.59 while delivering GAAP revenues of $1,020 million versus analyst expectations of $1,013.4 million. Revenues were flat year-over-year (–0.4%) and adjusted EBITDA reached $288 million, down 1.0% from Q2 2024. Free cash flow from continuing operations totaled $180 million, a 9.1% decline, though trailing twelve-month free cash flow improved by 13.7% to $939 million. Management reaffirmed full-year 2025 adjusted diluted EPS guidance in the range of $2.50 to $2.60 for continuing operations, without providing detailed revenue or segment outlooks. Investors will monitor Fortive’s ability to reaccelerate organic growth in its core segments, leverage the Fortive Business System for cost efficiency, and navigate external pressures such as trade policies and healthcare spending dynamics. On June 28, 2025, Fortive completed the Ralliant (Precision Technologies) spin-off, enabling greater focus on its two core segments: Intelligent Operating Solutions and Advanced Healthcare Solutions. Intelligent Operating Solutions delivered $697 million in Q2 revenue, unchanged year-over-year, and improved its adjusted EBITDA margin by 50 basis points. Advanced Healthcare Solutions faced a 1.3% revenue decline and a 1.9% drop in core revenue, but achieved modest margin gains on both GAAP operating profit and non-GAAP adjusted EBITDA lines. Fortive ended Q2 with cash and equivalents of $1,832.7 million, up significantly from the prior year, and returned $345 million to shareholders through share repurchases in the first half of 2025. The company maintained a conservative debt-to-equity ratio of 0.38 and declared dividends totaling $54.2 million for the six months ended June 27, 2025, underscoring disciplined capital allocation and liquidity management.
Fortive reported Q2 2025 adjusted diluted earnings per share of $0.58, narrowly missing consensus estimates of $0.59 while delivering GAAP revenues of $1,020 million versus analyst expectations of $1,013.4 million. Revenues were flat year-over-year (–0.4%) and adjusted EBITDA reached $288 million, down 1.0% from Q2 2024. Free cash flow from continuing operations totaled $180 million, a 9.1% decline, though trailing twelve-month free cash flow improved by 13.7% to $939 million. Management reaffirmed full-year 2025 adjusted diluted EPS guidance in the range of $2.50 to $2.60 for continuing operations, without providing detailed revenue or segment outlooks. Investors will monitor Fortive’s ability to reaccelerate organic growth in its core segments, leverage the Fortive Business System for cost efficiency, and navigate external pressures such as trade policies and healthcare spending dynamics. On June 28, 2025, Fortive completed the Ralliant (Precision Technologies) spin-off, enabling greater focus on its two core segments: Intelligent Operating Solutions and Advanced Healthcare Solutions. Intelligent Operating Solutions delivered $697 million in Q2 revenue, unchanged year-over-year, and improved its adjusted EBITDA margin by 50 basis points. Advanced Healthcare Solutions faced a 1.3% revenue decline and a 1.9% drop in core revenue, but achieved modest margin gains on both GAAP operating profit and non-GAAP adjusted EBITDA lines. Fortive ended Q2 with cash and equivalents of $1,832.7 million, up significantly from the prior year, and returned $345 million to shareholders through share repurchases in the first half of 2025. The company maintained a conservative debt-to-equity ratio of 0.38 and declared dividends totaling $54.2 million for the six months ended June 27, 2025, underscoring disciplined capital allocation and liquidity management.